US pharma major Eli Lilly (NYSE: LLY) spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy ...

The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, ...

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

Japan’s Otsuka has entered into an exclusive, worldwide licensing agreement with China and USA-based Harbour BioMed for the ...

The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair ...

Danish CNS specialist Lundbeck announced the full results from the Phase IV RESOLUTION trial at the 11th Congress of the ...

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has pointed to the role that it has played over ...

Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq ...

Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...